ArticleFrontiers in neurology
Protective effect of statins in patients with sepsis-associated encephalopathy: a retrospective cohort study.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis-associated encephalopathy (SAE) is a severe neurological complication of sepsis. Statins may exerted protective effects in sepsis and its complications by reducing the dysregulated inflammatory response. However, it remains unknown whether statins provide any protective effect on SAE. Methods: The data for this study were extracted from the MIMIC-IV database. Cox proportional hazards regression models were constructed to assess the association between statin therapy and mortality rate for in-hospital, 30-day, 90-day, 180-day, and 365-day. Kaplan-Meier survival curves were used to estimate survival probabilities between the non-statin group and statin group. Subgroup analysis was conducted to investigate potential variations in the effects of statin treatment on clinical outcomes among different groups. Results: A total of 4,707 patients with SAE were included in the study, with 2,387 in the non-statin group and 2,320 in the statin group. The findings indicated that the use of statins was linked to a considerable decrease in mortality rates. Patients who were administered statins experienced lower in-hospital mortality and demonstrated enhanced survival rates at 30, 90, 180, and 365 days when compared to those not receiving statins. Further analysis of atorvastatin showed that the subgroup exhibited a similarly consistent reduction in mortality across all time points in comparison to the non-statin group. Interestingly, the protective effect associated with statin use remained significant regardless of the statin type, dosage, or exposure time. Conclusion: The use of statins was associated with short-term and long-term mortality among SAE patients admitted to the ICU. This association was observed irrespective of statin type, dosage, or exposure time. It is necessary to conduct large-scale prospective studies to further explore the relationship between statins and the prognosis of patients with SAE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.